Remus Pharmaceuticals Ltd
Incorporated in 2015, Remus Pharma Ltd is in the business of trading and export of API and Finished Formulations and in Technical consultancy services[1]
- Market Cap ₹ 766 Cr.
- Current Price ₹ 650
- High / Low ₹ 1,140 / 580
- Stock P/E 22.9
- Book Value ₹ 261
- Dividend Yield 0.15 %
- ROCE 19.6 %
- ROE 14.0 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Debtor days have improved from 131 to 63.6 days.
- Company's working capital requirements have reduced from 76.0 days to 54.0 days
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|
| 213 | 620 | 748 | |
| 184 | 575 | 697 | |
| Operating Profit | 29 | 46 | 51 |
| OPM % | 14% | 7% | 7% |
| 3 | 5 | 6 | |
| Interest | 0 | 1 | 1 |
| Depreciation | 1 | 2 | 2 |
| Profit before tax | 30 | 47 | 53 |
| Tax % | 20% | 19% | |
| 24 | 38 | 42 | |
| EPS in Rs | 17.69 | 24.64 | 28.42 |
| Dividend Payout % | 4% | 3% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 63% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 20% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -35% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 14% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|
| Equity Capital | 1 | 6 | 12 |
| Reserves | 156 | 250 | 295 |
| 14 | 23 | 16 | |
| 161 | 154 | 245 | |
| Total Liabilities | 333 | 433 | 568 |
| 14 | 16 | 18 | |
| CWIP | 0 | 0 | 0 |
| Investments | 105 | 186 | 238 |
| 215 | 231 | 313 | |
| Total Assets | 333 | 433 | 568 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 1 | 7 | |
| -25 | -11 | |
| 28 | 6 | |
| Net Cash Flow | 4 | 3 |
| Free Cash Flow | -11 | 3 |
| CFO/OP | 25% | 32% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 198 | 64 |
| Inventory Days | 96 | 35 |
| Days Payable | 209 | 49 |
| Cash Conversion Cycle | 85 | 50 |
| Working Capital Days | 98 | 54 |
| ROCE % | 20% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Number of Registered Products Count |
|
||||
| Number of Commercialized Products Count |
|||||
| Number of Countries Presence Count |
|||||
| B2C Revenue Contribution % |
|||||
| New Product Approvals Count |
|||||
| Number of Manufacturing Partners (CMOs) Count |
|||||
| Number of Ready-to-File Dossiers Count |
|||||
| Total SKUs Count |
|||||
Extracted by Screener AI
Documents
Announcements
-
Structural Digital Database
17 April 2026 - PIT compliance certificate for FY2025-26 issued; six events captured, no non-compliances observed.
-
Disclosure under SEBI Takeover Regulations
10 April 2026 - Promoters disclosed NIL share encumbrance or pledge for year ended March 31, 2026.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
7 April 2026 - Filed Regulation 76 share capital reconciliation audit report for quarter ended March 31, 2026.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
7 April 2026 - Submitted Regulation 74(5) certificate for quarter ended March 31, 2026.
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
7 April 2026 - Remus Pharmaceuticals հայտնում non-applicability of Regulation 27(2) corporate governance reporting on SME Emerge platform.
Annual reports
Concalls
-
Nov 2025Transcript PPT
-
Aug 2025TranscriptAI SummaryPPT
-
May 2025Transcript PPT
-
Nov 2024Transcript PPT REC
Busienss Overview:[1][2]
RPL and its group of companies specialize in marketing pharmaceutical products with expertise in Critical Care, Neurology, Cardiology, and Diabetic categories, and recently getting off-patent molecules in various dosage forms and in complex generics. Company gets finished pharmaceutical formulations manufactured on loan license or contract manufacturing